Raymond James lowered the firm's price target on Old Republic to $44 from $47 and keeps a Strong Buy rating on the shares. The results reflect near-term pressure from ongoing investments in specialty insurance expansion, technology modernization, and a slower-than-expected recovery in the title segment, the analyst tells investors in a research note.